OBJECTIVE: We performed an impact and cost-effectiveness analysis of a novel HIV service delivery model in a high prevalence, remote district of Malawi with a population of 143 800 people. DESIGN: A population-based retrospective analysis of 1-year survival rates among newly enrolled HIV-positive patients at 682 health facilities throughout Malawi, comparing facilities implementing the service delivery model (n = 13) and those implementing care-as-usual (n = 669). METHODS: Through district-level health surveillance data, we evaluated 1-year survival rates among HIV patients newly enrolled between July 2013 and June 2014 - representing 129 938 patients in care across 682 health facilities - using a multilevel modeling framework. The model, focused on social determinants of health, was implemented throughout Neno District at 13 facilities and compared with facilities in all other districts. Activity-based costing was used to annualize financial and economic costs from a societal perspective. Incremental cost-effectiveness ratios were expressed as quality-adjusted life-years gained. RESULTS: The national average 1-year survival rate for newly enrolled antiretroviral therapy clients was 78.9%: this rate was 87.9% in Neno District, compared with 78.8% across all other districts in Malawi (P < 0.001; 95% confidence interval: 0.079-0.104). The economic cost of receiving care in Neno district (n = 6541 patients) was $317/patient/year, compared with an estimated $219/patient in other districts. This translated to $906 per quality-adjusted life-year gained. CONCLUSION: Neno District's comprehensive model of care, featuring a strong focus on the community, is $98 more expensive per capita per annum but demonstrates superior 1-year survival rates, despite its remote location. Moreover, it should be considered cost-effective by traditional international standards.
OBJECTIVE: We performed an impact and cost-effectiveness analysis of a novel HIV service delivery model in a high prevalence, remote district of Malawi with a population of 143 800 people. DESIGN: A population-based retrospective analysis of 1-year survival rates among newly enrolled HIV-positivepatients at 682 health facilities throughout Malawi, comparing facilities implementing the service delivery model (n = 13) and those implementing care-as-usual (n = 669). METHODS: Through district-level health surveillance data, we evaluated 1-year survival rates among HIV patients newly enrolled between July 2013 and June 2014 - representing 129 938 patients in care across 682 health facilities - using a multilevel modeling framework. The model, focused on social determinants of health, was implemented throughout Neno District at 13 facilities and compared with facilities in all other districts. Activity-based costing was used to annualize financial and economic costs from a societal perspective. Incremental cost-effectiveness ratios were expressed as quality-adjusted life-years gained. RESULTS: The national average 1-year survival rate for newly enrolled antiretroviral therapy clients was 78.9%: this rate was 87.9% in Neno District, compared with 78.8% across all other districts in Malawi (P < 0.001; 95% confidence interval: 0.079-0.104). The economic cost of receiving care in Neno district (n = 6541 patients) was $317/patient/year, compared with an estimated $219/patient in other districts. This translated to $906 per quality-adjusted life-year gained. CONCLUSION: Neno District's comprehensive model of care, featuring a strong focus on the community, is $98 more expensive per capita per annum but demonstrates superior 1-year survival rates, despite its remote location. Moreover, it should be considered cost-effective by traditional international standards.
Authors: Elizabeth L Dunbar; Emily B Wroe; Basimenye Nhlema; Chiyembekezo Kachimanga; Ravi Gupta; Celia Taylor; Annie Michaelis; Katie Cundale; Luckson Dullie; Arnold Jumbe; Lawrence Nazimera; Ryan McBain; Richard J Lilford; Samuel Ian Watson Journal: BMJ Open Date: 2018-07-13 Impact factor: 2.692
Authors: Emily B Wroe; Elizabeth L Dunbar; Noel Kalanga; Luckson Dullie; Chiyembekezo Kachimanga; Andrew Mganga; Michael Herce; Jason Beste; Jonas Rigodon; Lawrence Nazimera; Ryan K McBain Journal: BMJ Glob Health Date: 2018-01-12
Authors: Caroline A Bulstra; Jan A C Hontelez; Moritz Otto; Anna Stepanova; Erik Lamontagne; Anna Yakusik; Wafaa M El-Sadr; Tsitsi Apollo; Miriam Rabkin; Rifat Atun; Till Bärnighausen Journal: PLoS Med Date: 2021-11-09 Impact factor: 11.069
Authors: Natalie A Blackburn; Vivian F Go; Quynh Bui; Heidi Hutton; Radhika P Tampi; Teerada Sripaipan; Tran Viet Ha; Carl A Latkin; Shelley Golden; Carol Golin; Geetanjali Chander; Constantine Frangakis; Nisha Gottfredson; David W Dowdy Journal: AIDS Behav Date: 2021-01-03
Authors: Chiyembekezo Kachimanga; Elizabeth L Dunbar; Samuel Watson; Katie Cundale; Henry Makungwa; Emily B Wroe; Charles Malindi; Lawrence Nazimera; Daniel Palazuelos; Jeanel Drake; Thomas Gates; Thomas van den Akker; Jawaya Shea Journal: BMC Pregnancy Childbirth Date: 2020-01-06 Impact factor: 3.007